Evolving Paradigms in Lung Cancer: Clinical Integration of PD-(L)1 × VEGF Bispecific Therapy – Expert Podcast

This expert-led CME podcast features Dr. Edward Garon and Ann Fish-Steagall, who explore the evolving role of PD-(L)1 × VEGF bispecific therapies from both clinical and patient-care perspectives. Dr. Garon discusses the biological rationale for dual-pathway inhibition, emerging clinical evidence, and considerations for integrating bispecific therapies into the lung cancer treatment paradigm. Ann Fish-Steagall brings a patient services and clinical operations perspective, addressing access to clinical trials, shared decision-making, patient education, financial toxicity, and the practical challenges of monitoring and managing novel treatment-related toxicities. Through a practical, conversational discussion, the podcast highlights the importance of individualized patient selection, multidisciplinary coordination, proactive toxicity monitoring, and clear communication with patients and caregivers. Listeners will gain practical insights into how emerging evidence can be translated into day-to-day lung cancer care while supporting patients through treatment transitions and maintaining quality of life.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Cross-Specialty

Communication & Shared Decision-Making

Pricing

Free

Reported to ACCME by the provider

Podcast / audio
Credit · Up to 0.5 credits
Commercial Support

Released

Sep 8, 2026
Last day to claim credit

Jul 15, 2027 9 months left

Evolving Paradigms in Lung Cancer: Clinical Integration of PD-(L)1 × VEGF Bispecific Therapy – Expert Podcast

Related courses

More from Partners for Advancing Clinical Education